Apr 17, 2023 / 03:00PM GMT
Joseph Robert Stringer - Needham & Company, LLC, Research Division - Senior Analyst
Good morning, everyone. Thanks for joining the 22nd Annual Needham Healthcare Conference. My name is Jerry Stringer, and I'm one of the biotech analysts at Needham & Company. It's my pleasure to introduce our next presenting company, Ionis Pharmaceuticals. Joining us today from Ionis is Head of Investor Relations, Wade Walk. (Operator Instructions) So with that, we'll get started. Wade, thank you so much for joining us today.
Wade Walke -
Thank you, and thanks for having us here today. I appreciate being here.
Questions and Answers:
Joseph Robert Stringer - Needham & Company, LLC, Research Division - Senior AnalystYes. So Ionis, it's been one of the leaders in developing RNA-targeted therapeutics for a long time. Just wondering if you could give us your perspective on the past, the present and the future of Ionis' ASO approach.
Wade Walke -
You bet. Happy to. I actually joined Ionis over